1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Spencer Pharmaceutical Inc.

Spencer Pharmaceutical Inc.

SPPH
Spencer Pharmaceutical Inc.US flagOther OTC
0.00
USD
- -
- -
29,436.00Market Cap
2001 Y
2002 Y
2003 Y
TTM
Revenue per Share
1.35
3.52
- -
0.8
Basic EPS, GAAP
-3.18
-3
-1.1
-1.47
Free Cash Flow per Basic Share
0.16
-3.59
-0.98
-0.76
Dividend per Share
- -
- -
- -
- -
Book Value per Share
-3.18
-5.99
-1.49
-6.13
Tangible Book Value per Share
0.4
-0.56
4.93
0.69
Basic Weighted Avg Shares
1
1
1
1
Sales/Revenue/Turnover
1
3
- -
1
Operating Margin (%)
-238.44
-86.93
- -
-199.04
Depreciation Expense
1
- -
- -
- -
Net Income, GAAP
-2
-2
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
-236.42
-85.34
- -
-184.63
Working Capital
1
- -
- -
-1
LT Debt
- -
- -
- -
- -
Total Equity
- -
- -
4
4
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'03
Dec'03
Mar'04
ST Debt
- -
- -
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
1
1
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'03
Dec'03
Mar'04
Total Current Assets
1
- -
1
Cash, Cash Equivalents & STI
1
- -
- -
Accounts Receivable, Net
- -
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
2
Payables & Accruals
- -
- -
1
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-1,018.44%
Free Cash Flow
- -
- -
-71.26%
Net Income, GAAP
- -
- -
-61.49%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2002
- -
- -
- -
1
3
2003
- -
- -
- -
- -
- -
2004
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2002
-1.19
-1.3
-0.71
- -
-3
2003
-0.18
-0.26
-0.09
- -
-1.1
2004
-0.39
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2002
- -
- -
- -
- -
- -
2003
- -
- -
- -
- -
- -
2004
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Maximilien Arella
Full Time Employees
2
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
8 Faneuil Hall Marketplace Boston United States of America
IPO Date
Feb 7, 2023
Website
spencerpharmaceutical.com
Similar Companies
PetMed Express, Inc. (PETS)
Ligand Pharmaceuticals, Inc. (LGNZZ)
Spencer Pharmaceutical Inc. (SPPH)
111, Inc. (YI)
Mezzion Pharma Co.,Ltd. (140410.KQ)
Vilin Bio Med Ltd. (VILINBIO.NS)
Business
Spencer Pharmaceutical Inc. (SPPH) develops drug platform technologies focused on controlled-release formulations of existing therapeutic molecules for neurological diseases and other conditions. The company specializes in treatments targeting Alzheimer's disease, Parkinson's disease, multiple sclerosis, and brain cancer through central nervous system delivery systems; it also offers a patented slow-release drug delivery technology applicable to type-2 diabetes, arthritis, and additional indications. Founded in 1998 and headquartered in Boston, Canada, Spencer Pharmaceutical maintains primary operations in North America and Europe. In recent years, the company has reported no major funding rounds, acquisitions, partnerships, or new product launches within the last 1-2 years, with its last reported earnings dating to 2010 and ongoing OTC trading amid limited revenue generation. Historical developments include a 2009 reverse merger with Emergensys Corp. and prior research agreements, such as with the University of Quebec in Montreal, though no significant strategic shifts or expansions have been announced recently.